Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

65.31USD
25 Sep 2017
Change (% chg)

$0.18 (+0.28%)
Prev Close
$65.13
Open
$65.16
Day's High
$65.38
Day's Low
$65.11
Volume
339,850
Avg. Vol
8,208,244
52-wk High
$66.80
52-wk Low
$58.29

Latest Key Developments (Source: Significant Developments)

Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients
Friday, 22 Sep 2017 03:30pm EDT 

Sept 22 (Reuters) - Merck & Co Inc :Fda approves Merck’s keytruda® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1).FDA ‍approves co's keytruda (pembrolizumab) for previously treated patients.Approval for Keytruda was based on data from trial Keynote-059​.  Full Article

Sanofi files suit in U.S. to defend patent rights on Lantus
Tuesday, 8 Aug 2017 03:32pm EDT 

Aug 8 (Reuters) - Sanofi SA ::Sanofi files suit in the U.S. to defend its patent rights on Lantus.Says ‍filed a patent infringement suit against Merck Sharp & Dohme Corp​.Says ‍in its suit co alleges infringement of two patents​.  Full Article

FDA approves first cancer treatment for solid tumor with specific genetic feature
Tuesday, 23 May 2017 03:04pm EDT 

May 23 (Reuters) - U.S. FDA::FDA approves first cancer treatment for any solid tumor with a specific genetic feature.Says granted accelerated approval to treatment for patients whose cancers have a specific genetic feature (biomarker).Says granted accelerated approval of keytruda to merck & co.  Full Article

Merck sets quarterly dividend of $0.47 per share
Tuesday, 23 May 2017 01:19pm EDT 

May 23 (Reuters) - Merck : :Sets quarterly dividend of $0.47 per share.  Full Article

Merck unit says confident it complied with UK competition law
Tuesday, 23 May 2017 04:53am EDT 

May 23 (Reuters) - Merck :Unit MSD says cooperating fully with UK CMA’s ongoing investigation on Remicade.MSD says confident proceedings will show it complied with competition law at all times.MSD says discounts meant infliximab was competitively priced and offered savings to UK NHS, without hindering competition.  Full Article

UK's CMA issues statement of objections to Merck's unit
Tuesday, 23 May 2017 04:30am EDT 

May 23 (Reuters) - UK's Competition And Markets Authority::Issued a statement of objections to pharmaceutical company Merck Sharp & Dohme Limited (MSD).Provisionally found that MSD broke competition law by abusing its dominant position through a discount scheme for Remicade.Sets out competition and markets authority's provisional decision MSD operated anti-competitive discount scheme for its medicine Remicade."Proposes to find MSD and its ultimate parent company Merck & Co Inc jointly and severally liable for alleged infringement".  Full Article

Aurinia completes licensing deal with Merck Animal Health
Monday, 17 Apr 2017 04:02pm EDT 

April 17 (Reuters) - Aurinia Pharmaceuticals Inc -:Aurinia completes licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome.Aurinia Pharma-signed agreement granting merck animal health worldwide rights to develop, commercialize co's nanomicellar voclosporin ophthalmic solution.Aurinia Pharma-under deal, co will receive upfront payment, is eligible to receive further payments based on certain development and sales milestones.Aurinia Pharmaceuticals Inc- under deal, aurinia will receive royalties based on global product sales.Aurinia Pharma- under deal merck animal health to be responsible for remaining clinical development, commercialization of vos for use in animal health field.Aurinia pharmaceuticals inc- under deal aurinia retains all human health rights related to vos.  Full Article

Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial
Tuesday, 14 Feb 2017 04:05pm EST 

Merck & Co Inc : Merck's doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial . Merck's doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial . Merck - data presented at croi showed doravirine was non-inferior to ritonavir-boosted darunavir in treatment-naïve adults after 48 weeks of treatment . Says study met its primary efficacy endpoint .Merck & Co - secondary endpoint showed that dor-treated group had statistically significant lower levels of fasting low density lipoprotein cholesterol.  Full Article

Boehringer Ingelheim - To evaluate Afatinib in combination with PD-1 inhibitor pembrolizumab
Thursday, 9 Feb 2017 08:30am EST 

Boehringer Ingelheim : Boehringer Ingelheim - afatinib to be evaluated in combination with pd-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of lung .Boehringer Ingelheim - continues to explore afatinib beyond large lux-lung programme and its current indications.  Full Article

Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine
Tuesday, 17 Jan 2017 09:00am EST 

Agenus Inc : Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine .Agenus says under collaboration, Agenus will supply Prophage, Merck will provide pembrolizumab and NCI and BTTC member sites will recruit patients and conduct trial.  Full Article

BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients

* Fda approves Merck’s keytruda® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1)